NC-318
- Generic Name
- NC-318
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
Phase 1
Withdrawn
- Conditions
- Advanced or Metastatic Solid TumorsNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- NextCure, Inc.
- Registration Number
- NCT04430933
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Endometrial CancerMelanomaLung CancerHead and Neck Squamous Cell CarcinomaUrothelial CarcinomaAdvanced or Metastatic Solid TumorsBreast CancerCRCCholangiocarcinoma
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT03665285
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath